DYAI earnings

JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended March 31, 2026 and host a corporate update conference call on Wednesday, May 13, 2026. Conference Call Information Date: Wednesday, May 13, 2026 Time: 5:00 p.m. Eastern Tim

Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnershipSigned an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recombinant DNase I and transferrin for research and cell culture applications through IBT's global distribution channelsEntered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-

JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the year ended December 31, 2025 and host a corporate update conference call on Wednesday, March 25, 2026. Conference Call Information Date: Wednesday, March 25, 2026 Time: 5:00 p.m. Eastern

JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, November 12, 2025. Conference Call Information Date: Wednesday, November 12, 2025 Time: 5:00 p.m. Eastern Tim

JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, August 13, 2025. Conference Call Information Date: Wednesday, August 13, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-

Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programsSelected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.Scientific Pre-Publication – "Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1"Cash, cash equivalents and invest

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20

JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the year ended 2024 and host a corporate update conference call on Wednesday, March 26, 2025. Conference Call Information Date: Wednesday, March 26, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-85

Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license fees and milestone payments.Received $1 million milestone payment for animal-free recombinant albumin products.Received $425,000 success fees for achieving production targets in a dairy enzyme collaboration.Expanded recombinant life science protein portfolio within six additional products in development for molecular biology and cell culture media applications. Human Health Co-developed a highly productive C1-produced ferritin nanoparticle Mpox (mo

JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the third quarter 2024 and host a corporate update conference call on Tuesday, November 12, 2024. Conference Call Information: Date: Tuesday, November 12, 2024Time: 5:00 p.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560Conference

Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint development agreement with a Top 10 global dairy company for the development of non-animal alpha-lactalbuminOngoing development of a robust pipeline of non-pharmaceutical recombinant product candidates such as alpha-lactalbumin, transferrin, DNASE-1, and several potential biofuels and other enzymes utilizing the Dapibus™ platform technology Animal Health Provided samples of the C1-produced recombinant ferritin nanoparticle H5 Clade 2.3.3.4.b A/Astrakhan avian influenza ‘Bird Flu' antigen to multi

JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the second quarter 2024 and host a corporate update conference call on Tuesday, August 13, 2024. Conference Call Information: Date: Tuesday, August 13, 2024 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560 Confere

Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against COVID-19 infectionEntered into several fully funded vaccine and antibody projects covering more than twelve targets, five of which are funded by two of the top ten pharmaceutical companiesSuccessfully expressed a H1N1 influenza antigen in our collaboration with the Vaccine and Immunotherapy Center ("VIC") at Massachusetts General HospitalAnnounced strategic partnership to develop affordable rabies prophylactics and vaccin

JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the first quarter 2024 and host a corporate update conference call on Tuesday, May 14, 2024. Conference Call Information: Date: Tuesday, May 14, 2024 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560 Conference ID

Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein receptor binding domain (RBD) booster vaccine candidate for protection against COVID-19 infection Entered into several fully funded vaccine and antibody projects covering more than twelve targets since announcing topline clinical safety data from First-In-Human Phase 1 trial Executed a term sheet to utilize our microbial protein production platforms to develop production strains for the production of recombinant serum albumin initiall

JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that it will report its financial results for the year ended 2023 and host a corporate update conference call on Thursday, March 28, 2024. Conference Call Information Date: Thursday, March 28, 2024

Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme products DYAI-100 Phase 1 clinical trial top-line results expected in December 2023 New research collaboration with Vaccine and Immunotherapy Center at Massachusetts General Hospital as part of US $5.88 million awards from the Department of Defense ("DoD") New development and commercialization agreement with bYoRNA to develop cost-effective messenger RNA (mRNA) Ongoing preclinical animal studies showing positive results with high neutralizing antibody levels for seasonal and pandemic flu and other infectious diseases Expanded leadership tea

JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the third quarter 2023 and host a corporate update conference call on Wednesday, November 8, 2023. Conference Call Information Date: Wednesday, November 8, 2023 T

Positive Interim Phase 1 clinical trial safety results for C1 platform for manufacturing human vaccines Two MoU's with Fondazione Biotecnopolo di Siena in Italy and Essential Drugs Company Limited (EDCL) in Bangladesh Progress in developing animal-free recombinant serum albumin with initial positive analytical results and casein proteins with Dapibus™ cell lines New C1 ferritin nanoparticle antigens; initiated infectious disease animal studies to combat bird flu, encephalitis and meningitisMultiple new fully funded research collaborations with: A Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human health in a large infectious disease segmentA new animal health com

New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic One Health ("Rubic") to develop, manufacture and commercialize affordable vaccines and biologics for human and animal health for African ContinentExpanded collaboration with Phibro/Abic animal health to develop vaccines for animal diseasesFully funded co-development and marketing agreement with Fermbox to use Dapibus™ platform to develop and commercialize animal free alternative proteins and biomaterialsNo serious adverse events or local and systemic side effects reported after completion of dosing of DYAI-100 recombinant protein RBD b

JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a corporate update conference call on Wednesday, May 10, 2023. Conference Call Information Date: Wednesday, May 10, 2023 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: 877-407-0784; Inter

Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate which has completed dosing of all patients in both the low and high dose testing groupsOngoing research and license agreements with Janssen, Hengrui, NIIMBL and others for the C1-expressed therapeutic proteins for human health Expanded collaboration with Phibro/Abic and others to develop vaccines and treatments for companion and livestock animal diseasesInitiated multiple product candidates to support the newly launched Dapibus™ platform, a fungal-based microbi

JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it will report its financial results for the year ended 2022 and host a corporate update conference call on Wednesday, March 29, 2023. Conference Call Information Date: Wednesday, March 29, 2023 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: 877-407-0784; International +

Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein RBD booster vaccine candidatePresented safety, efficacy, and productivity data at World Vaccine Congress EuropeNew and expanded collaborations with top animal health companies to develop vaccines and treatments for companion and livestock animal diseasesInitiated multiple product candidates to support the newly launched Dapibus™ platform, a fungal-based microbial platform for use in non-pharmaceutical applications such as food, nutrition, health, and wellnessC

JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it will report its financial results for the third quarter 2022 and host a corporate update conference call on Thursday, November 10, 2022. Conference Call Information Date: Thursday, November 10, 2022 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: 877-407-0784; Internati

Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from proprietary C1-cell protein production platform and demonstrate preliminary efficacy of DYAI-100 COVID-19 recombinant protein booster vaccineExpressed biologically active neuraminidase (NA) protein for influenza at high levels from C1-cells which demonstrates the ability to generate high neutralizing antibodies in animal studyEnhancing Company's focus in three core verticals: Human Health, Animal Health, and Alternative ProteinsLaunched the Dapibus™ platform, a fungal-based microbial platform for use

JUPITER, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for the second quarter 2022 and host a corporate update conference call on Wednesday, August 10, 2022. Conference Call Information Date: Wednesday, August 10, 2022 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free:

New research, license, and collaboration agreement with a Global Food Ingredients Company using Dyadic's proprietary biotechnologiesLicense agreement with Phibro/Abic Animal Health to develop and commercialize animal vaccine(s)Advancing first-in-human clinical trial application (CTA) to South African Health Products Regulatory Authority (SAHPRA) to support clinical safety of C1 produced proteinsC1 produced COVID-19 monoclonal antibody (mAb) demonstrated broad neutralization and protection against Omicron (BA.1 & BA.2) and other variants of concern in hamster trialLicensee, Epygen Biotech, received funding from India government to continue development, manufacture and conduct Phase I/II clini

JUPITER, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for the first quarter 2022 and host a corporate update conference call on Thursday, May 12, 2022. Conference Call Information Date: Thursday, May 12, 2022 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: 800-289-

New research, license and collaboration agreement with Janssen for the development and manufacture of therapeutic proteinsReceived NIIMBL coronavirus grant of $690,000 under the White House's American Rescue PlanNew license agreement with Phibro Animal Health to develop and commercialize certain animal health vaccinesExpecting to advance proprietary DYAI-100 COVID-19 vaccine candidate towards first-in-human clinical trialExecutive leadership team enhanced with the appointment of Joseph Hazelton as Chief Business OfficerManuscripts published in three highly regarded vaccine scientific journalsPeer reviewed manuscript demonstrating safety and persistence of C1-cell produced DYAI-100 vaccine ca

JUPITER, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for 2021 year-end and host a corporate update conference call on Tuesday, March 29, 2022. Conference Call Information Date: Tuesday, March 29, 2022 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: 877-407-0784 In

 ●COVID-19 vaccine candidate, DYAI-100, continues to advance towards first-in-human clinical trial to validate C1 produced proteins are safe in humans and further accelerate global C1 platform adoption ●Five non-COVID-19 infectious disease monoclonal antibody and antigen development programs are ongoing ●Animal health vaccine project continues to demonstrate safety and efficacy advancing towards potential commercialization ●Entered two new fully funded R&D collaborations with academia and industry  ●Executive leadership team enhanced with the appointment of Joseph Hazelton, Chief Business Officer   ●Received $1.6M in cash from sale of equity interest in BDI ●Licensing Agreement discussions c

JUPITER, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update conference call on Wednesday, November 10, 2021. Conference Call Information Date: Wednesday, November 10, 2021 Time: 5:00 p.m. Eastern Time

Executed binding term sheet with Sorrento Therapeutics (NASDAQ:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidateNew collaboration with India's Syngene International to develop a COVID-19 vaccine candidateNew co-development collaboration with South Africa's Rubic consortium to establish a basis for researching, developing, and manufacturing multiple other C1 produced vaccines in addition to DYAI-100Potential to support vaccine production for up to 100% of the world's populationDyadic's C1 productio

JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended June 30, 2021 and host a corporate update conference call on Thursday, August 12, 2021.Conference Call InformationDate: Thursday, August 12, 2021Time: 5:00 p.m. Eastern TimeDial-in numbers: Toll Free: 888-506-0062 I

Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial Goal of validating that C1 produced proteins are safe in humans and to accelerate adoption and use of C1 technology platform for the development and manufacture of vaccines and therapeuticsGoal of bringing larger quantities of lower cost COVID-19 vaccines that can be used as a prime and booster to existing vaccinesEngaged CR2O to manage and support further preclinical and clinical development Initiated toxicology studycGMP manufacturing run in progress Collaborating on next-generation COVID-19 variant vaccines and/or boosters through Korea and Southeast Asia vaccine developmen

Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercialization To serve as proof of concept for next-generation multivalent COVID-19 vaccine candidates Expanded Korea and Southeast Asia vaccine development partnership with Medytox (086900) (KOSDAQ) focused on next-generation COVID-19 variant vaccines and/or boosters In parallel with DYAI-100, additional proprietary and third-party COVID-19 variant vaccine candidates are under development Developing a number of other infectious disease vaccines and antibodies internally and